What is the likely cause of early‑morning sweats and transient hot flashes in a 56‑year‑old male with acute myeloid leukemia who completed intensive 7+3 chemotherapy, had a normal complete blood count and bone marrow aspirate indicating remission on day 23, was discharged on day 24, and now on day 26 presents with these symptoms?

Early Morning Sweats and Hot Flashes Post-AML Chemotherapy

The most likely cause is an infectious complication, specifically early febrile neutropenia or an occult infection, despite the normal CBC on day 23. Early morning sweats and transient hot flashes in this clinical context should trigger immediate evaluation for infection, as neutropenic patients post-intensive chemotherapy remain at high risk even after apparent count recovery 1.

Primary Differential Diagnosis

1. Infectious Etiology (Most Likely)

The timing is critical here—only 2 days post-discharge after intensive 7+3 chemotherapy. Despite the normal CBC on day 23, several factors make infection the primary concern:

• Delayed neutropenia or functional immune deficiency: Even with recovered counts, immune function remains compromised for weeks after intensive AML chemotherapy 1
• Early morning sweats with fever are classic for occult bacterial or fungal infections in this population
• The standard of care requires empirical antibiotic approach for any fever or concerning symptoms in recent AML chemotherapy patients 1

Immediate actions required:

• Urgent CBC with differential to assess for neutropenia recurrence
• Blood cultures (bacterial and fungal) before any antibiotics
• Comprehensive metabolic panel and inflammatory markers (CRP, procalcitonin)
• Chest imaging (CT preferred over plain film) to evaluate for pneumonia or invasive fungal disease 2
• Temperature monitoring every 4 hours

2. Fungal Infection Risk

Given the 7+3 protocol causes prolonged profound neutropenia, invasive fungal disease remains a concern even post-recovery 2:

• Invasive aspergillosis can present with subtle symptoms initially
• Disseminated candidiasis may manifest with intermittent fevers and sweats
• High-resolution chest CT should be performed urgently if any respiratory symptoms or persistent fever develops 2

3. Less Likely but Consider:

Sweet's syndrome (febrile neutrophilic dermatosis): Can occur after remission induction chemotherapy for AML, presenting with fever and sweats 3, 4. However, this typically includes characteristic skin lesions (erythematous papules/plaques on face, neck, trunk), which are not mentioned here.

Critical Management Algorithm

Immediate (Within Hours):

1. Contact patient urgently for temperature measurement and symptom assessment
2. If temperature ≥38°C (100.4°F) or patient appears ill: Direct to emergency department immediately
3. Obtain cultures before antibiotics: blood (peripheral and central line if present), urine, any other clinically indicated sites

If Febrile or Clinically Unstable:

• Initiate broad-spectrum antibiotics immediately (e.g., piperacillin-tazobactam or ceftazidime plus aminoglycoside) 2
• Do not wait for culture results in neutropenic or recently neutropenic AML patients 1
• Consider empirical antifungal coverage if patient had prolonged neutropenia (>7 days) during induction 2

If Afebrile but Symptomatic:

• Same-day evaluation with complete workup
• Close monitoring (temperature every 4 hours)
• Low threshold for admission and empirical antibiotics

Common Pitfalls to Avoid

1. False reassurance from day 23 normal counts: Immune reconstitution takes weeks; functional neutropenia persists 1
2. Dismissing symptoms as "minor": Early morning sweats in this population are never benign until proven otherwise
3. Delaying evaluation: Infections in post-chemotherapy AML patients can progress rapidly to sepsis
4. Assuming non-infectious cause first: Always rule out infection before considering other etiologies in this high-risk population

Alternative Diagnoses (Only After Infection Excluded)

• Hormonal/autonomic dysregulation from chemotherapy (extremely unlikely in males and would be diagnosis of exclusion)
• Residual disease/relapse (too early and contradicted by day 23 bone marrow showing remission)
• Drug-related effects (no ongoing medications mentioned that would cause this)

The standard of care mandates treating this as potential infection until proven otherwise 1, 2. Any delay in evaluation or empirical treatment could result in life-threatening sepsis in this immunocompromised patient.